miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	BOHOŠOVÁ Júlia JURÁČEK Jaroslav POPRACH Alexandr BUCHLER T. FIALA O. RADOVÁ Lenka SVOBODA Marek KOPKOVÁ Alena VEČEŘA Marek SLABÝ Ondřej
Year of publication	2019
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation
Description	Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
Related projects:	Molecular classification of renal cell carcinoma based on long noncoding RNAs expression and its implication for diagnosis, prognosis and therapy